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Cancer	Therapy:	Viral	oncolysis.			As	a	post-doctoral	fellow	in	the	laboratory	of	John	Holland	I	learned	to	grow	tumor	cells	in	the	body	cavity	of	mice.	These	were	tumors	that	arose	spontaneously	in	mice,	had	been	grown	in	culture	or	maintained	by	passage	through	mice	for	many	years,	were	easy	to	transplant,	and	grew	rapidly.	They	were	100%	lethal	to	the	mice..		One	held	the	mouse	by	the	 back	 of	 the	 neck,	 as	 one	would	 pick	 up	 a	 cat,	 and	 injected	 the	 tumor	 into	 the	 body	cavity.	 	 Within	 a	 few	 days	 the	 abdominal	 cavity	 puffed	 up	 like	 a	 balloon.	 It	 was	 rather	horrible	,	and	after	a	week	to	ten	days	the	animal	could	barely	move.		The	tumor	cells	were	harvested	 by	withdrawing	 them	with	 a	 syringe	 from	 the	 body	 cavity,	 and	 cells	 could	 be	kept	“	alive”	by	placing	them	into	a	flask	with	media.	We	used	these	cells	for	RNA	isolation.	In	particular	this	approach	worked	with	standard	tumor	cells	lines	such	as	Ehrlich	Ascites	Carcinoma	 (	 originally	 isolated	 by	 Paul	 Ehrlich	 )	 and	 sarcomas.	We	 could	 harvest	 large	amounts	of	cells,	free	of	contamination.			I	really	do	not	remember	how	the	idea	arose	to	produce	virus	in	these	tumors	after	transplanting	them	into	the	animal.	I	thought	it	might	be	a	way	of	reproducing	the	virus	in	large	 amounts	without	 the	 need	 of	 cell	 culture.	 I	 myself	 did	 the	 original	 experiment,	 of	injecting	bovine	enterovirus-1,	which	we	happened	to	have	handy	(again	brought	with	me	from	 the	 Holland	 lab),	 and	 	 injecting	 the	 virus	 into	 a	 few	 animals.	 	 To	 my	 surprise	 the	tumors	regressed	within	a	day	or	so	and	the	mice	returned	to	a	healthy	appearance.	I	was	very	excited	by	this	discovery	and	felt	I	had	made	an	important	novel	scientific	discovery.	A	cure	for	cancer!	The	magic	bullet!	I	decided	this	was	worth	pursuing	further	and	asked	an	undergraduate	 (JD	 and	 now	 a	 retired	 professor	 at	 Lexington	 Kentucky)	 working	 on	 an	independent	project	to	test	this	further,	and	discussed	the	phenomenon	with	some	of	the	my	graduate	students.		We	then	tested	the	virus,	(BEV)	against	a	large	number	of	tumor	cell	lines.	In	all	cases,	both	in	vivo		(in	the	mouse)	and	in	vitro		(cell	culture)	the	virus	destroyed	the	tumors.			Quite	a	number	of	students	were	involved	in	this	work,	including	Suzanne	Prather,	the	wife	of	Larry	Prather	who	was	the	department	“	 tech”	person.	While	studying	 for	 the	Ph.D.	she	was	diagnosed	with	breast	cancer.	After	receiving	her	Ph.D.	she	took	a	position	at	
the	University	of	Nebraska,	but	died	a	few	years	later.	She	was	a	very	strong	willed	person,	not	wanting	to	give	up,	and	fought	her	cancer	vigorously,	suffering	through	many	surgeries.	She	would	come	to	the	lab	on	crutches	as	the	cancer	spread.		Others	involved	in	this	work	include	Gerry	Sedmak,	a	red	headed	graduate	student,	who	was	difficult	to	distinguish	from	his	twin	brother,	who	was	also	in	the	department.	The	brother,	James	(Jim)	went	on	to	work	in	the	field	of	interferon.		I	probably	have	met	them	both	at	scientific	meetings,	not	able	to	tell	them	apart.		Others	working	on	this	project	were	Barbara	 Cordell_Stewart,	 and	 a	 visiting	 physician	 	Magda	 Souhrada.	Magda	 had	 recently	arrived	 from	 Czechoslovakia,	 	 having	 fled	 after	 the	 Soviet	 invasion	 of	 the	 country.	 	 Her	husband	had	found	a	job	in	the	physics	department,	and	although	a	MD	she	could	not	work	in	 that	 capacity	 until	 she	 passed	 exams	 to	 practice	medicine.	 After	 a	 year	 or	 so	 she	 did	begin	working	with	Dr	Riley	Schaffer,	a	local	pediatrician.	.Barbara	was	a	graduate	student.	A	perusal	of	scientific–cancer	literature	indicated	that	this	unfortunately	was	not	a	novel	finding	but	an	old	phenomenon,	reported		many	years	ago.	Viruses	of	various	origins	were	used	to	treat	cancer		in	both	the	US	and	in	Japan	going	back	to	the	1940’s.	This	was	based	on	an	 	observation	made	around	 the	1900’s	 that	 some	patients	with	 cancers	went	into	remission	after	a	viral	infection	or	rabies	vaccination.	 	 	At	that	time	viruses	were	still	unknown	entities.	It	was	not	clear		in	the	1940’s	whether	this	resulted	from	activation		of	the	immune	response	or	due	to	direct	action	of	the	virus	on	the	tumor,	or	a	combination	of	both.	A	 large	body	of	research	was	performed	in	the	US	 in	the	1940’s	and	1950’s	 testing	various	viruses,	particularly	exotic	ones,	that	is	viruses	that	occurred	predominantly	in	the	tropics,	on	terminal	cancer	patients	,with	only	limited	results.		Most	patients	died,	but	there	was	 some	 objective	 regression	 of	 tumor	 mass.	 These	 patients	 were	 terminally	 ill	 when	treatment	was	 initiated.	 .This	 research	was	 discredited	 in	 the	 1950’s	when	 it	was	 found	that	patients	in	one	hospital	had	been	injected	with	cancer	cells	to	test	the	effect	of	various	anti-cancer	agents	including	virus.		In	most	cases	the	injected	tumors	were	rejected	by	the	immune	system,	although	occasionally	 they	had	to	be	surgically	removed.	The	researcher	involved	 was	 later	 criticized	 for	 this	 type	 of	 work,	 since	 he	 had	 not	 gone	 through	 the	normal	protocols	for	protection	of	human	subjects	even	at	that	time.	I	am	not	certain	there	was	a	human	subjects	committee.		
A	group	 in	 Japan	used	mumps	virus	to	 treat	a	 large	number	of	patients	with	some	transient	effect	on	tumor	growth.	There	was	some	limited	success	with	the	prolongation	of	life	of	terminal	cancer	patients,	but	the	treatment	was	not	performed	in	sufficient	numbers	to	 be	 statistically	 significant.	 The	 experiments	 in	 Japan,	 although	 performed	 better	 than	those	done	in	the	US	had	very	mixed	results.	It	was	obvious	that	before	this	could	proceed	to	the	clinic	there	was	need	for	considerable	basic	research.		I	 therefore	 asked	 some	 graduate	 students	 and	 undergraduates	 to	 work	 out	 the	basics:	and	we	decided	to	use	BEV-1	as	a	model	viral	system.	We	published	a	number	of	papers	on	viral	oncolysis,	or	virotherapy	as	 this	phenomenon	 is	now	called,	 in	 influential	journals	(Nature	New	Biology,	PNAS).	 	BEV-1	destroyed	tumors	of	various	kinds,	not	only	ascites	 tumors	 and	 not	 only	 in	 mice.	 In	 collaboration	 with	 Dr.	 E.	 Hodes	 at	 the	 Medical	School	we	 showed	 that	 the	 virus	 also	 destroyed	 tumors	 of	 rabbits	 and	 dogs.	 If	we	 could	obtain	 the	 funding	we	were	set	 to	begin	 clinical	 trials.	However	 I,	 and	others	working	 in	viral	 oncolysis,	 found	 it	 difficult	 to	 obtain	grants.	 The	 idea	 that	 viruses	 could	 be	 used	 as	therapeutic	agents	in	the	1970s	was	way	before	its	time.		Until	very	recently	is	was	difficult	to	get	funded	by	the	NIH	for	this	type	of	work.		When	 we	 published	 our	 papers	 on	 viral	 oncolysis,	 the	 local	 and	 national	 press	picked	up	the	story,	after	a	press	release	by	the	IU	news	department.	I	received	letters	and	phone	calls	from	as	far	away	as	Australia	asking	for	the	virus	to	treat	tumors	in	dogs	and	in	humans.	 I	constantly	had	to	point	out	 that	 this	was	an	experimental	system.	 I	had	a	visit	from	two	scientists	from	Japan,	Dr.	Teruo	Asada	and	Dr.	Yamanishsi	from	Osaka	University,	to	consult	and	discuss	their	results	with	mumps	virus.	The	Japanese	scientists	came	laden	with	presents.	One	of	my	colleagues	Bob	Togasaki	acted	as	interpreter.	I	 just	noted	on	Dr.	Asada’s	 paper	 in	 Cancer,	 1974,	 that	he	 thanked	myself,	 and	Dr.	Hodes	of	 Indianapolis	 as	well	as	Dr.	Togasaki	for	discussions	of	the	work.	I	remember	that	we	hosted	them	at	home,	Mimi	prepared	an	elegant	dinner	(as	usual)	and	they	came	laden	with	presents.	It	was	a	bit	like	Xmas,	presents	 for	Mimi	(pearls),	presents	 for	 the	house,	 for	Dr.	and	Mrs.	Togasaki.	 I	did	 not	 quite	 know	 how	 to	 respond,	 but	 Bob	 Togasaki’s	 advice	 was	 not	 to	 reciprocate	otherwise	the	exchange	of	presents	would	go	on	forever.		In	a	way	this	was	my	moment	of	
fame.	The	work	was	quoted	in	many	sources.		I	received	acclaim	from	the	American	Cancer	Society,	and	I	found	it	very	hard	to	let	go.		However	 because	 of	 lack	 of	 funding	 viral	 oncolysis	 lay	 dormant	 as	 a	 project	 for	 quite	 a	number	of	years	and	I	became	involved	much	more	with	other	projects.	One	can	question	my	judgment,	in	whether	it	was	wise	to	give	this	up,	or	in	fact	would	have	been	better	to	re-apply	 for	 funding	 and	 continue	 the	work.	My	 attitude,	 which	 in	 hindsight	was	 probably	wrong,	was	to	give	up	on	a	project	that	was	not	funded	the	first	or	second	time	around.	I	have	 learned	 from	my	 colleagues	 and	 having	been	 on	many	 grant	 study	 sections,	 that	 it	may	 take	 multiple	 re-writes	 to	 satisfy	 everyone	 on	 a	 study	 section	 committee,	 and	 to	 “	knock”	the	score	up	by	a	few	points	so	that	it	is	within	the	fundable	range.		However	at	that	time	there	seemed	no	future	in	viral	oncolysis.	I	went	for	a	job	interview	at	the	university	of	Georgia	in	the	late	1970’s	(I	am	not	certain	I	would	have	even	moved),	but	although	my	talk	went	down	well,	my	host,	the	chairman	of	the	department	took	me	aside	and	told	me	he	thought	I	was	working	in	the	wrong	area.	An	area	without	a	future.	He	may	have	been	correct,	but	 it	 is	difficult	 to	give	up	an	 idea	 that	 seemed	so	promising.	Today	 I	 am	much	more	skeptical	about	research	in	general,	certainly	as	to	its	applications.	Basic	research	for	knowledge	sake	is	something	else.		Today,	fifty	years	later	experiments	treating	cancer	with	a	virus	is	still	being	pursued	and	in	China	viruses		(adenovirus	and	herpes	viruses)	are	used	in	the	clinic	in	combination	with	chemotherapy	 or	 other	 treatments.	 Quite	 a	 number	 of	 biotech	 companies	 have	 been	launched	with	this	idea,	and	just	as	many	have	folded.		Amgen,	the	company	I	worked	with	in	 the	1990’s	has	 just	bought	out	another	biotech	 company	B-vec	 for	1	billion	dollars	 to	explore	viral	oncolysis.	Currently	a	modified	herpes	virus	containing	a	gene	associated	with	the	immune	system	(GM-CSF)	is	undergoing	phase	3	trials	for	the	treatment	of	melanoma	and	head	and	neck	cancer.	The	reported	rate	of	remission	 for	melanoma	is	25%	with	the	virus	 containing	 the	 GM-CSF	 gene	 and	 only	 2%	 using	 GM-CSF	 alone.	 Other	 oncolytic-modified	viruses	are	being	 tested	 in	 the	presence	of	 chemotherapeutic	 agents	with	some	success.	It	appears	that	the	obstacles	to	viral	therapy	are	still	the	ones	we	discussed	in	the	1970’s.	 These	 include	 how	 to	 get	 the	 virus	 to	 the	 target,	 the	 immune	 and	 interferon	response	against	 the	virus,	 the	development	of	 antibodies	against	 the	virus,	 and	possible	
adverse	effects	of	the	virus.		These	same	obstacles	have	hindered	progress	in	gene	therapy,	and	 are	 difficult	 to	 overcome.	 	 However	 viruses	 have	 been	 engineered,	 by	 deleting	 or	adding	genes,	sometimes	from	non-viral	sources	that	overcome	many	of	these	difficulties.		Viral	oncolysis	reappeared	again	 in	my	own	career	many	years	 later	when	we	did	experiments	using	another	virus	 (adenovirus)	 in	gene	 therapy	experiments	using	a	virus	carrying	 an	 interferon	 gene.	 	 That	 is	 a	 separate	 story	 under	 the	 heading	 gene	 therapy.	Perhaps	I	should	go	back	to	BEV,	modify	the	virus,	and	restart	my	career.			
